First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist

Journal of clinical pharmacology

Volumn 54, Issue 12, 2014, Pages 1347-1353

  Timmer, Wolfgang ^a   Massana, Eric ^a   Jimenez, Eulalia ^a   Seoane, Beatriz ^a   de Miquel, Gonzalo ^a   Ruiz, Sandrine ^a  

^a Clinical Research Services Mannheim GmbH   (Germany)

Author keywords

abediterol; asthma; COPD; healthy adults; long acting 2 agonist

Indexed keywords

5-(2-((6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL)AMINO)-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; QUINOLONE DERIVATIVE;

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; BRONCHODILATOR AGENTS; HUMANS; MALE; QUINOLONES; SINGLE-BLIND METHOD;

EID: 84964315337     PISSN: None     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.355     Document Type: Article

References (0)